Skip to main content

Table 3 Univariable and multivariable Cox regression models for the prediction of institutionalization and mortality in AD dementia patients

From: Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease

 

Institutionalization

Mortality

Univariable

Model 1

Model 2

Univariable

Model 1

Model 2

 

Age and sex adjusted

 

Without CSF

Without CSF/MRI

 

Age and sex adjusted

 

Without CSF

Without CSF/MRI

Age

1.00

(0.99; 1.01)

1.00

(0.99; 1.01)

1.00

(0.98; 1.01)

1.00

(0.99; 1.02)

1.02

(1.00; 1.04)

1.02*

(1.01; 1.04)

1.02*

(1.01; 1.04)

1.02

(1.00; 1.03)

1.02

(1.00; 1.03)

1.03

(1.01; 1.04)

Sex, female

0.95

(0.79; 1.15)

0.95

(0.79; 1.15)

0.93

(0.77; 1.13)

0.94

(0.78; 1.14)

0.88

(0.73; 1.07)

0.76*

(0.63; 0.92)

0.76*

(0.63; 0.92)

0.70

(0.57; 0.85)

0.70

(0.57; 0.85)

0.71

(0.58; 0.86)

MMSE

0.93*

(0.91;0.94)

0.93*

(0.91; 0.94)

0.94

(0.92; 0.96)

0.93

(0.92; 0.95)

0.93

(0.91; 0.94)

0.93*

(0.92; 0.95)

0.93*

(0.91; 0.94)

0.94

(0.92; 0.95)

0.94

(0.92; 0.95)

0.93

(0.91; 0.95)

NPI

1.03*

(1.02; 1.04)

1.03*

(1.02; 1.04)

1.03

(1.02; 1.04)

1.03

(1.02; 1.04)

1.03

(1.02; 1.04)

1.02*

(1.01; 1.03)

1.02*

(1.01; 1.03)

1.01

(1.00; 1.02)

1.01

(1.00; 1.02)

1.01

(1.00; 1.02)

CCI

1.00

(0.93; 1.08)

1.00

(0.91; 1.11)

  

0.90

(0.81; 1.00)

1.16*

(1.08; 1.25)

1.13*

(1.02; 1.24)

   

APOE e4

1.03

(0.84; 1.26)

1.03

(0.84; 1.26)

   

0.93

(0.76; 1.15)

0.94

(0.77; 1.16)

   

GCA

1.26*

(1.07; 1.48)

1.28*

(1.08; 1.50)

   

1.49*

(1.26; 1.76)

1.43*

(1.20; 1.69)

1.21

(1.01; 1.45)

1.21

(1.01; 1.45)

 

MTA

1.37*

(1.20; 1.56)

1.43*

(1.24; 1.64)

1.34

(1.15; 1.55)

1.30

(1.12; 1.51)

 

1.39*

(1.23; 1.58)

1.32*

(1.15; 1.51)

   

WMH

0.97

(0.85; 1.09)

0.96

(0.84; 1.10)

0.84

(0.75; 0.96)

0.83

(0.72; 0.95)

 

1.30*

(1.14; 1.48)

1.27*

(1.10; 1.46)

1.18

(1.02; 1.35)

1.18

(1.02; 1.35)

 

CSF Aβ42a

1.00

(0.96; 1.03)

0.99

(0.96; 1.03)

   

0.96*

(0.92; 0.99)

0.95*

(0.92; 0.99)

   

CSF p-tau

1.01*

(1.00; 1.01)

1.01*

(1.00; 1.01)

1.01

(1.00; 1.01)

  

1.01*

(1.00; 1.01)

1.01*

(1.00; 1.01)

   

Harrell’s C

  

0.68

(0.65; 0.70)

0.68

(0.65; 0.70)

0.67

(0.64; 0.70)

  

0.65

(0.62; 0.68)

0.65

(0.62; 0.68)

0.65

(0.62; 0.68)

3-year Brier score

  

0.174

(0.161; 0.187)

0.174

(0.161; 0.187)

0.177

(0.164; 0.190)

  

0.091

(0.077; 0.105)

0.091

(0.077; 0.105)

0.091

(0.077; 0.105)

  1. Data is represented as Hazard Ratio (95%CI) and Harrell’s C (95%CI)
  2. We used all variables as continuous variables in the models, except for the dichotomous variables gender and APOE e4
  3. AD Alzheimer’s disease, 95%CI 95% confidence interval, NPI Neuropsychiatric Inventory, MMSE Mini-Mental State Examination, CCI Charlson Comorbidity Index, GCA global cortical atrophy, MTA medial temporal lobe atrophy, WMH white matter hyperintensities, CSF cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181
  4. aHazard ratio for every 100pg/ml
  5. *p<0.05 in univariate analysis
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193